116 related articles for article (PubMed ID: 27888385)
1. Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy.
Zheng T; Yang CG
Sci China Life Sci; 2017 Jan; 60(1):91-93. PubMed ID: 27888385
[No Abstract] [Full Text] [Related]
2. Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
Guo ZQ; Zheng T; Chen B; Luo C; Ouyang S; Gong S; Li J; Mao LL; Lian F; Yang Y; Huang Y; Li L; Lu J; Zhang B; Zhou L; Ding H; Gao Z; Zhou L; Li G; Zhou R; Chen K; Liu J; Wen Y; Gong L; Ke Y; Yang SD; Qiu XB; Zhang N; Ren J; Zhong D; Yang CG; Liu J; Jiang H
Cancer Cell; 2016 Sep; 30(3):474-484. PubMed ID: 27622336
[TBL] [Abstract][Full Text] [Related]
3. SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma.
Zhao W; Zhou J; Deng Z; Gao Y; Cheng Y
Int J Oncol; 2016 Sep; 49(3):1001-8. PubMed ID: 27572476
[TBL] [Abstract][Full Text] [Related]
4. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.
Li G; Ci W; Karmakar S; Chen K; Dhar R; Fan Z; Guo Z; Zhang J; Ke Y; Wang L; Zhuang M; Hu S; Li X; Zhou L; Li X; Calabrese MF; Watson ER; Prasad SM; Rinker-Schaeffer C; Eggener SE; Stricker T; Tian Y; Schulman BA; Liu J; White KP
Cancer Cell; 2014 Apr; 25(4):455-68. PubMed ID: 24656772
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer.
Liu J; Ghanim M; Xue L; Brown CD; Iossifov I; Angeletti C; Hua S; Nègre N; Ludwig M; Stricker T; Al-Ahmadie HA; Tretiakova M; Camp RL; Perera-Alberto M; Rimm DL; Xu T; Rzhetsky A; White KP
Science; 2009 Feb; 323(5918):1218-22. PubMed ID: 19164706
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in small molecule therapies for renal cell carcinoma.
Song M
Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
[TBL] [Abstract][Full Text] [Related]
7. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression.
Wang L; Lin M; Chu M; Liu Y; Ma J; He Y; Wang ZW
EBioMedicine; 2020 Jun; 56():102795. PubMed ID: 32460168
[TBL] [Abstract][Full Text] [Related]
8. Decade in review-kidney cancer: discoveries, therapies and opportunities.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2014 Nov; 11(11):614-6. PubMed ID: 25287783
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
11. Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling.
Cheng S; Castillo V; Eliaz I; Sliva D
Int J Oncol; 2015; 46(6):2293-8. PubMed ID: 25846316
[TBL] [Abstract][Full Text] [Related]
12. G Protein Alpha S Subunit Promotes Cell Proliferation of Renal Cell Carcinoma with Involvement of Protein Kinase A Signaling.
Zhang B; Sun N; Mu X; Zhi L; Zhai L; Jiang Y; Fu Z; Yao Z
DNA Cell Biol; 2017 Mar; 36(3):237-242. PubMed ID: 28051330
[TBL] [Abstract][Full Text] [Related]
13. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
14. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
Srinivasan R; Linehan WM
J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
[No Abstract] [Full Text] [Related]
15. [Therapeutic indication of interferons for renal cell carcinoma].
Harano M; Naito S
Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
[No Abstract] [Full Text] [Related]
16. [Targeted therapy for renal cell carcinoma].
Terai K; Horie S
Nihon Jinzo Gakkai Shi; 2016; 58(4):568-72. PubMed ID: 27416700
[No Abstract] [Full Text] [Related]
17. What's new in renal cell carcinoma.
Meng MV; Nelson H
Bull Am Coll Surg; 2012 Aug; 97(8):65-6. PubMed ID: 22973751
[No Abstract] [Full Text] [Related]
18. The pluripotent renal stem cell regulator SIX2 is activated in renal neoplasms and influences cellular proliferation and migration.
Senanayake U; Koller K; Pichler M; Leuschner I; Strohmaier H; Hadler U; Das S; Hoefler G; Guertl B
Hum Pathol; 2013 Mar; 44(3):336-45. PubMed ID: 22995329
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenetics of renal cancer.
Skolarikos AA; Papatsoris AG; Alivizatos G; Deliveliotis C
Am J Nephrol; 2006; 26(3):218-31. PubMed ID: 16733347
[TBL] [Abstract][Full Text] [Related]
20. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
